The recent update to ISO 15223-1, formalized through Amendment 1:2025, ushers in a critical shift for medical device labeling ...

The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) announced a groundbreaking decision on April 22, 2025. The agencies plan to phase out all ...

The U.S. Department of Health and Human Services and U.S. Food and Drug Administration announced it would phase out all petroleum-based synthetic dyes from the United States' food supply and ...

The HHS Secretary announced plans to phase out several petroleum-based dyes used by major food brands — and it all has to ...

U.S. health officials on Tuesday said they would urge food makers to phase out petroleum-based artificial colors in the ...

On April 10, 2025, the Food and Drug Administration (FDA) released a pre-recorded webinar outlining the updated "healthy" nutrient content claim ...

CMND-100 is Clearmind’s proprietary MEAI-based oral drug candidate, developed as a potential breakthrough treatment for AUD. Unlike traditional treatment methods, CMND-100 is designed to offer a novel ...

Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus Yervoy (ipilimumab). The regulatory body approved Opdivo plus Yervoy as a ...

Michael Moye, President and General Manager of Idorsia US, commented: "The fact that the FDA has expedited the approval of the updated TRYVIO label to remove the REMS requirements is, I believe ...

Michael Moye, President and General Manager of Idorsia US, commented: “The fact that the FDA has expedited the approval of the updated TRYVIO label to remove the REMS requirements is, I believe, a ...

Michael Moye, President and General Manager of Idorsia US, commented: “The fact that the FDA has expedited the approval of the updated TRYVIO label to remove the REMS requirements is ...